GA-map® Dysbiosis Test

Power your lab to become a market leader in the microbiome testing segment

GA-map® Dysbiosis Test is a clinically validated assay for microbiome profiling in both research and clinical diagnostics.

Strengthen your analysis portfolio with a standardized IVD microbiome test.

CE-IVD marked

Reproducible

Clinically validated

Short turnaround

Routine microbiome test

GA-map® Dysbiosis Test is a CE-IVD gut microbiome test suitable for routine testing. The assay is clinically validated and standardized, providing highly reliable and easy to interpret results. Easy assay workflow, high throughput capacity and integrated software enable short turnaround and automatic patient report generation.

GA-map® Dysbiosis Test - assay specifications

Sample type

Stool

Read-out platform

MAGPIX®, Luminex®200™

Assay time

8 hours, pre-extracted samples

Output

Patient report including Dysbiosis Index, analyte abundance and microbiota functional profile

Assay format

48-plex, 1 well/sample

Easy-to-read test results

With GA-map® Dysbiosis Test, the need for comprehensive result calculations in gut microbiota testing is obsolete. The raw data are processed through a unique algorithm and compared to a healthy reference population to obtain clinically meaningful results.

The results are presented in an easy to read report form based on information from 48 preselected bacteria markers, included in the panel because of their discriminatory power in distinction between normal and dysbiotic gut.




Download a sample report for free below.

Dysbiosis Index (DI), measured on a 5-point scale from 1 (normobiosis) to 5 (severe dysbiosis), where DI values>2 indicate the presence of dysbiosis. DI value indicates the extent to which the bacteria profile of a sample deviates from a normal, healthy reference population.

50+ publications

An increasing number of researchers have discovered the efficiency and simplicity of the GA-map® Dysbiosis Test in gut microbiota analysis.

Utilizing the GA-map technology drastically reduces the time from analysis to publication, through merging the rapidness, preciseness, and robustness of RT-PCR approaches with the comprehensiveness of next-generation sequencing methods. GA-map® Dysbiosis Test has until now been applied in clinical research in the fields of gastroenterology (IBS and IBD) and metabolic disorders (Diabetes and Obesity).

GA-map® Dysbiosis Test

Reference values

Relative abundance compared to healthy normal

No data processing steps

Patented algorithm providing ready-to-use results

Dysbiosis Index

Validated dysbiosis indicator

CE-IVD marked

Meets high safety, health, and environmental requirements

GA-map® global network

Contact us today to learn more about the GA-map® Dysbiosis Test performing Labs worldwide

We used GA-map® in our clinical research within IBS. We have great experience with GA-map® as a tool to select, monitor and follow-up patients.

Professor Magdy El-Salhy

Stord Hospital, Helse Bergen and the University of Bergen, Norway

Professor Magdy El-Salhy

There is still so much to learn about the microbiome, we are only just beginning to discover its importance, and the GA-map Test will help us do just that.

Emeritus Professor Peter Malfertheiner

Senior Professor at the Ludwig Maximillian University, University Clinic in Munich, Germany

Emeritus Professor Peter Malfertheiner

Get started with GA-map®

Curious to learn more? We're happy to answer your questions.